# US 10,864,259 B2 · Methods and compositions for the treatment of melanoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,259 B2
- Document ID: US10864259B2
- Status: Granted
- Kind: B2
- Application number: 16/184,086
- Filed: 2018-11-08
- Published: 2019-02-28
- Granted: 2020-12-15
- Earliest claimed: 2017-08-03
- Assignees: Taiga Biotechnologies, Inc.
- Applicants: Taiga Biotechnologies, Inc.
- Inventors: Yosef Refaeli; Brian C. Turner; Gregory Alan Bird
- Web page: https://patentgrep.com/patent/US10864259B2

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/0011: {Cancer antigens}
- A61K 40/10: characterised by the cell type used
- A61K 40/4242: {Transcription factors, e.g. SOX or c-MYC}
- A61K 40/46: Viral antigens
- C12N 5/0638: {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}
- A61K 2039/515: {Animal cells}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/57: Skin; melanoma
- C12N 2501/606: c-Myc
- C12N 2510/00: Genetically modified cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are methods and compositions for the treatment of melanoma using anti-tumor immune cells treated with a PTD-MYC fusion protein (e.g., an HIV TAT-MYC fusion protein).

## Claims

### Claim 1

A composition comprising:
(a) a MYC fusion peptide, comprising (i) a protein transduction domain; (ii) a MYC polypeptide sequence, wherein the MYC fusion peptide comprises SEQ ID NO: 1; and
(b) one or more primary immune cells from a donor subject that has a melanoma tumor, wherein the one or more primary immune cells are reactive against a melanoma-specific antigen.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the protein transduction domain sequence is a TAT protein transduction domain sequence.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the one or more immune cells comprises a T cell, a B cell, an NK cell, or any combination thereof.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the one or more immune cells comprises a tumor-infiltrating lymphocyte, T-cell receptor modified lymphocyte, or a chimeric antigen receptor modified lymphocyte.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the tumor-infiltrating lymphocyte has a CD8+CD25+ signature or a CD4+CD25+ signature.